Compare CYBN & VALU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CYBN | VALU |
|---|---|---|
| Founded | 2019 | 1931 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 298.9M | 340.4M |
| IPO Year | N/A | N/A |
| Metric | CYBN | VALU |
|---|---|---|
| Price | $6.62 | $37.52 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $74.50 | N/A |
| AVG Volume (30 Days) | ★ 626.1K | 3.1K |
| Earning Date | 11-13-2025 | 12-15-2025 |
| Dividend Yield | N/A | ★ 3.42% |
| EPS Growth | N/A | ★ 6.17 |
| EPS | N/A | ★ 2.26 |
| Revenue | N/A | ★ $34,801,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $16.85 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.81 | $32.94 |
| 52 Week High | $10.73 | $55.01 |
| Indicator | CYBN | VALU |
|---|---|---|
| Relative Strength Index (RSI) | 60.06 | 57.80 |
| Support Level | $5.70 | $37.07 |
| Resistance Level | $6.20 | $39.20 |
| Average True Range (ATR) | 0.35 | 0.77 |
| MACD | 0.08 | 0.27 |
| Stochastic Oscillator | 85.82 | 84.23 |
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.
Value Line Inc is a U.S based company. It produces investment periodicals based on underlying research and making available copyright data, including ranking system and other information, to third parties under written agreements for use in third-party managed and marketed investment products and for other purposes. The company markets under brands including Value Line, the Value Line logo, The Value Line Investment Survey, Smart Research, Smarter Investing and a trusted name in Investment Research. Its only operating segment being Publishing.